| Connexon Creative Inc is pleased to present this special issue of Cell Therapy News dedicated to Phacilitate Cell and Gene Therapy Symposium. Special issues are used to provide information that is of particular interest to our readers.
Phacilitate Cell & Gene Therapy Forum 200828-30 January. The Grand Hyatt, Washington DC Co-sponsored by Maxcyte, Inc & Lonza The Phacilitate Cell & Gene Therapy Forum is firmly established as the world's only event to cater specifically for the knowledge exchange, benchmarking and networking needs of senior management from the cell-, tissue- and gene-based therapy industries: - Unique audience! As evidenced by the list of 70+ confirmed speakers, no other meeting attracts as many senior representatives from the major industry players, as well as key decision-makers from big pharma, big biotech, the finance community, the major regulatory agencies and other public sector stakeholders.
- Unique program! Unlike any other event for the cell, tissue and gene therapy community, the Cell & Gene Therapy Forum explores scientific, regulatory, corporate and manufacturing challenges from a strategic perspective, with a specific focus on therapies as products moving towards licensure and the marketplace. No other meeting provides such invaluable strategic insights and practical advice tailored to inform your key business decisions moving forwards.
- Unique networking opportunity! Phacilitate events are renowned the world over for cultivating the sort of exclusive, informal, yet business-focused environment that is proven to be ideal for top-level networking with existing and potential future clients and partners. A carefully planned conference schedule provides you with ample opportunity to meet and mingle with the public and private sector decision-makers who have the power to directly impact your business.
VISIT WWW.PHACILITATE.CO.UK/CGTHERAPY FOR MORE INFORMATION AND ONLINE REGISTRATION FACILITIES. Key benefits of attending Attend the Cell & Gene Therapy Forum to: - Access leading VCs and other investors involved in the global cell, tissue and gene therapy fields
- Align your regulatory strategy with evolving guidelines and legislation in North America, Europe and the Far East
- Inform your manufacturing strategy through balanced assessment of in-house as well as outsourcing options
- Prepare your product for the marketplace by hearing from companies on the cusp of commercialization - what are their ongoing regulatory (filing a BLA, navigating pre-approval inspections), pricing and reimbursement strategies?
- Identify R&D and commercial opportunities on a truly global basis, with speakers from four continents already confirmed
- Discover what leading analysts are expecting for the sector moving forwards
- Assess big pharma's ongoing plans for involvement in the cell and gene therapy area - what are they now looking for in a potential partner?
- Discuss the pros and cons of developing cell, tissue and gene therapy products in combination with delivery devices
- Analyse the latest clinical data from leading cell and gene therapy candidates in clinical development - in which indications, and with which technologies, is the greatest progress being made?
- Compare and contrast various business diversification models with the potential to secure the long-term future of your organization
- Clarify what data is required and which animal models you should adopt to swiftly and successfully transition from preclinical development to first-in-man studies
- Define a pathway towards successfully characterizing your product - how do you develop a potency assay for a cell or gene therapy?
- Learn from experts in other fields, gaining insights into successful product development and commercialization strategies from biologics that are already established on the market
- Benchmark your R&D and product development strategies against those of your competitors
- NETWORK with senior level representatives of all the major cell and gene therapy industry players, the regulators and other key government bodies, and investors and analysts.
Visit http://www.phacilitate.co.uk/pages/cgtherapy2008/agenda.html for the full program.
Don't miss Progenitor Cell Therapy's lunch briefing on day 2 of the event:
Collaborating to accelerate the development of cellular therapies
Presenter: Stewart Craig, PhD, Vice President & Chief Technology Officer, Progenitor Cell Therapy LLC
Speaker panel Attend the Cell & Gene Therapy Forum to hear from and meet 70+ senior speakers, including: - Earl M. Collier, Executive Vice President, Genzyme Corporation
- Dr Alan Sachs, Vice President, RNA Therapeutics, Merck Research Laboratories
- Dr Karen Kozarsky, Head, Gene Therapy, Biopharmaceutical CEDD, GlaxoSmithKline
- Sudha Kadiyala, PhD, Worldwide Director, Business Development & Strategic Planning, Johnson & Johnson Regenerative Therapeutics, LLC
- Dr Naomi Aronson, Executive Director, Technology Evaluation Center (TEC), BlueCross & BlueShield Association
- Dr Mitchell H. Gold, President & CEO, Dendreon Corporation
- Stephen Potter, Senior Vice President, Corporate Development, Genzyme Corporation
- Dr John McNeish, Senior Director, Pfizer Global R&D
- Daniel Takefman, PhD, Chief, Gene Therapy Branch, Division of Cellular & Gene Therapy, OCTGT/CBER, US FDA
- Professor Ryuichi Morishita, Professor, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine & Founder, Board Member, AnGes MG
- Jeffrey M. Ostrove, PhD, President & CEO, Ceregene, Inc
- Dr Peter Working, Senior Vice President, R&D, Cell Genesys
- Dr Garheng Kong, General Partner, Intersouth Partners
- Gabor M. Rubanyi, MD, PhD, CSO, Cardium Therapeutics, Inc
- Dr Madhusudan V. Peshwa, Vice President, Research & Development, Maxcyte, Inc
- Professor Klaus Cichutek, Vice President & Head, Division Medical Biotechnology, Paul-Ehrlich-Institut & Chair, EMEA Gene Therapy Working Party
- Ed Field, President & COO, Aldagen, Inc
- Linda Powers, Managing Director & Co-Founder, Toucan Capital Fund II & Chair, Maryland Stem Cell Commission
- Dr Shelly Heimfeld, Director, Cellular Therapy Laboratory & cGMP Cell Processing Facility, Fred Hutchinson Cancer Research Center
- Dr Akihiro Shimosaka, Director, EPS Co. Ltd
- Dr Silviu Itescu, CEO, Angioblast Systems, Inc
- Geert-Jan Mulder, MD, General Partner, Forbion Capital Partners
- Dr Kai Pinkernell, Senior Director, Regenerative Cell Technology, Cytori Therapeutics, Inc
- Elmar R. Burchardt, MD, PhD, Vice President, Medical Affairs, Aastrom Biosciences, Inc
- John LeGuyader, Director, Technology Center 1600, United States Patent & Trademark Office
- Dr Wendy Naimark, R&D Manager, Boston Scientific Corporation
- Gregory A. Bonfiglio, Managing Partner, Proteus Venture Partners
- Dr Ram Mandalam, Vice President of Pharmaceutical Operations, Cellerant Therapeutics, Inc
Visit http://www.phacilitate.co.uk/pages/cgtherapy2008/speakers.html for the full speaker list. CONTACT NICOLA McCALL AT NICOLA@PHACILITATE.CO.UK (TEL: +44 (0)20 7839 6137) FOR MORE INFORMATION ON GROUP DISCOUNTS AND SMALL COMPANY/ACADEMIC/GOVERNMENT RATES. The exhibition The Cell & Gene Therapy Forum runs concurrently with Phacilitate's Washington Vaccine Forum, with all networking activities shared in a central exhibit area. 500+ senior level attendees are expected in total. Visit http://www.phacilitate.co.uk/pages/cgtherapy2008/sp_exhibition_opps.html for the latest floorplan and information on sponsorship options. 40+ exhibitors have already confirmed their participation! |
